Nature Reviews Rheumatology - Table of Contents alert Volume 13 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2017 Volume 13 Number 2
2015 2-year Impact Factor 10.531 Journal Metrics 2-year Median 7	In this issue Research Highlights Year in Review Reviews Perspectives Also this month  Featured article: Inflammatory mechanisms in tendinopathy — towards translation Neal L. Millar, George A. C. Murrell & Iain B. McInnes
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Paediatric rheumatic disease: Systemic JIA genetically distinct Published online: 12 January 2017 p65 | doi:10.1038/nrrheum.2016.215 PDF Systemic lupus erythematosus: iNKT cells guard the heart against disease Published online: 22 December 2016 p66 | doi:10.1038/nrrheum.2016.216 PDF Rheumatoid arthritis: New model linking periodontitis and RA Published online: 05 January 2017 p66 | doi:10.1038/nrrheum.2016.221 PDF
YEAR IN REVIEW		Top
Regenerative medicine in 2016: Important milestones on the way to clinical translation Daniel A. Grande Published online: 05 January 2017 p67 | doi:10.1038/nrrheum.2016.214 Regenerative medicine can be viewed as 'tissue engineering V2.0'. Discoveries and novel applications of technology advanced the field considerably in 2016, with the use of new biomaterials, stem cells and biologically active molecules. Full Text | PDF
Systemic Lupus Erythematosus in 2016: Gene expression profiling comes closer to the clinic Guillermo Barturen & Marta E. Alarcón-Riquelme Published online: 05 January 2017 p69 | doi:10.1038/nrrheum.2016.211 Gene expression profiling has been used for the first time to stratify patients with systemic lupus erythematosus (SLE) into potentially useful clinical groups, and also to further understand differences in the cell-specificity and nature of the interferon signature typical of SLE and other autoimmune diseases. Full Text | PDF
Systemic sclerosis in 2016: Dermal white adipose tissue implicated in SSc pathogenesis John Varga & Roberta G. Marangoni Published online: 12 January 2017 p71 | doi:10.1038/nrrheum.2016.223 Several strands of new research indicate that skin-specific adipocyte progenitor cells regulate myofibroblasts and skin fibrosis in scleroderma. Full Text | PDF
Microbiome in 2016: T follicular helper cells and the gut microbiome in arthritis Veena Taneja Published online: 12 January 2017 p72 | doi:10.1038/nrrheum.2016.222 Rheumatoid arthritis is associated with an expansion of certain gut commensals, although the underlying mechanism remains unknown. In 2016, studies using experimental models of arthritis have begun to unravel the links between the gut microbiota, T follicular helper cells and arthritis. Full Text | PDF
Myositis in 2016: New tools for diagnosis and therapy Ingrid E. Lundberg Published online: 25 January 2017 p74 | doi:10.1038/nrrheum.2017.1 In 2016, there have been several major scientific achievements related to myositis, including the discovery of a novel autoantibody and the relationship between autoantibodies and distinct clinical phenotypes. Advances in the way clinical trials are conducted have also led to breakthroughs in treatment strategies. Full Text | PDF
Osteoarthritis in 2016: Anti-NGF treatments for pain — two steps forward, one step back? Nancy E. Lane & Maripat Corr Published online: 25 January 2017 p76 | doi:10.1038/nrrheum.2016.224 Inhibitors of β-nerve growth factor (NGF) have impressive effects in reducing musculoskeletal pain, but have also been associated with adverse events of unclear aetiology. Several studies in the past year have sought to clarify the relative benefits and risks of anti-NGF treatment. Full Text | PDF
REVIEWS		Top
Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis Anca I. Catrina, Camilla I. Svensson, Vivianne Malmström, Georg Schett & Lars Klareskog Published online: 15 December 2016 p79 | doi:10.1038/nrrheum.2016.200 How and why systemic autoimmunity targets the joints in rheumatoid arthritis remains a major unanswered question. In this Review, Catrina et al. discuss the evidence for a driving role for osteoclasts in the homing of autoimmunity to the joints. Abstract | Full Text | PDF
Immune resolution mechanisms in inflammatory arthritis Mauro Perretti, Dianne Cooper, Jesmond Dalli & Lucy V. Norling Published online: 05 January 2017 p87 | doi:10.1038/nrrheum.2016.193 The authors discuss the preclinical evidence that provides insights into the mechanisms, pathways and mediators that set in motion resolution of inflammation. The time is ripe to establish if, and how, this biology can inform therapeutic innovation in the context of chronic inflammatory diseases. Abstract | Full Text | PDF
Leptin in the interplay of inflammation, metabolism and immune system disorders Vanessa Abella, Morena Scotece, Javier Conde, Jesús Pino, Miguel Angel Gonzalez-Gay, Juan J. Gómez-Reino, Antonio Mera, Francisca Lago, Rodolfo Gómez & Oreste Gualillo Published online: 05 January 2017 p100 | doi:10.1038/nrrheum.2016.209 Leptin is involved in regulating bone mass, basal metabolism and insulin secretion, among other processes. This Review explores the role of leptin in the immune system and metabolism, with particular emphasis on its effect on autoimmune and inflammatory rheumatic diseases. Abstract | Full Text | PDF
Inflammatory mechanisms in tendinopathy - towards translation Neal L. Millar, George A. C. Murrell & Iain B. McInnes Published online: 25 January 2017 p110 | doi:10.1038/nrrheum.2016.213 Tendon disorders are common and confer a large socioeconomic burden. This Review discusses the role of inflammatory mechanisms in tendon homeostasis and resolution of tendon damage, which are crucial to consider in developing novel therapeutics for tendinopathies. Abstract | Full Text | PDF
PERSPECTIVES		Top
SCIENCE AND SOCIETY An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology Nikolay P. Nikolov & Marjorie A. Shapiro Published online: 05 January 2017 p123 | doi:10.1038/nrrheum.2016.204 The goal of a development programme for a biosimilar product is to prove its biosimilarity to the reference product, rather than independently establish its safety and efficacy. In this Perspectives article, the authors describe the US FDA's rigorous approach to the assessment of biosimilarity for proposed biosimilar therapeutic proteins, including those intended to treat rheumatologic conditions. Abstract | Full Text | PDF
Advertisement
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.